Document is current

Article History

Received: 20 December 2023

Accepted: 25 January 2024

First Online: 13 February 2024

Declarations

:

: Andrea Bever, Jessica Dunne and Shelagh Szabo are employees of Broadstreet HEOR, which received funds from Asthma Canada for this work. Jenna Reynolds is an employee of Asthma Canada. Asthma Canada receives funding from AstraZeneca, GSK, Sanofi, Pfizer, Teva, Novartis, Janssen and Valeo. Alan Kaplan reports consulting fees or honoraria from ALK, AstraZeneca, Bellus, BI, Covis, Eisai, GSK, Merck Frosst, Moderna, Novo Nordisk, Pfizer Sanofi, Teva, Trudell, Valeo; Chairperson of Family Physician Airways Group of Canada; Vice president of Respiratory Effectiveness Group. AGK is an honorary professor of primary care Respiratory Research, Observational and Pragmatic Research Institute; Medical director, local pulmonary rehabilitation program; Board member, Thrombosis Canada; Senate member of the International Primary Care Respiratory Group. Andrew O'Keefe reports research funding from Sanofi; Honoraria for speaking activities from Novartis, ALK, Innomar, Medexus, GSK, Sanofi; Consultancy meetings with ALK, Sanofi, Takeda and Astra Zeneca. Stacey McNeilly reports no conflicts. Susan Waserman reports consulting fees from GSK, Novartis, CSL Behring, Pfizer Canada, Sanofi Canada, AstraZeneca, Takeda, ALK Abello, Teva, Medexus, MiravoHealth, Mylan, Bausch Lomb, AbbVie, Avir Pharma, Leo Pharma,Valeo; research grants from Pfizer Canada, Alk Abello, Aimmune; is current President of Canadian Allergy, Asthma and Immunology Foundation; is currently on the Board of Directors for Asthma Canada.

: This study received ethics approval from WCG IRB Canada on June 22, 2022. This study was conducted in accordance with the Helsinki Declaration of 1964 and its later amendments.

: All study participants were provided with an informed consent document in advance of being interviewed. This document noted that the results of the study may be published in the scientific literature, although information would be de-identified. Verbal informed consent was received prior to the interview, once the participant had an opportunity to discuss the consent document with their interviewer and it was determined that any questions related to participation in the study had been satisfactorily answered.